Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

by Zacks Equity Research

J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.

    Zacks Equity Research

    The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

      Zacks Equity Research

      Why Multiple Sclerosis is a Promising but Risky Space?

      by Zacks Equity Research

      Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.

        Zacks Equity Research

        Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie

        by Zacks Equity Research

        Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie

          Zacks Equity Research

          AbbVie's Uterine Fibroids Candidate Succeeds in Phase III

          by Zacks Equity Research

          AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.

            Tracey Ryniec headshot

            The Best Marijuana Stocks Right Now

            by Tracey Ryniec

            It is getting easier to buy stocks that do business in the emerging cannibis industry. Tracey and Dave explore all the options.

              Zacks Equity Research

              Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens

              by Zacks Equity Research

              Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens

                Tracey Ryniec headshot

                Want to be a Buy and Hold Investor? 3 Strategies

                by Tracey Ryniec

                It takes more than guts to hold a stock for 40 or 50 years in a portfolio. What lessons can be learned from those who have done it?

                  Tracey Ryniec headshot

                  Want to be a Buy and Hold Investor? 3 Strategies

                  by Tracey Ryniec

                  It takes more than guts to hold a stock for 40 or 50 years in a portfolio. What lessons can be learned from those who have done it?

                    Zacks Equity Research

                    Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta

                    by Zacks Equity Research

                    The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.

                      Sweta Killa headshot

                      Profit From Share Buyback Boom With These ETFs

                      by Sweta Killa

                      2018 is expected to be the second-busiest year for buybacks since the bull market began in 2009 buoyed by the new tax law.

                        Zacks Equity Research

                        Gilead Announces Positive Data on New HIV Therapy Biktarvy

                        by Zacks Equity Research

                        Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

                          Zacks Equity Research

                          4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

                          by Zacks Equity Research

                          Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

                            Zacks Equity Research

                            Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP

                            by Zacks Equity Research

                            CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.

                              Zacks Equity Research

                              AbbVie (ABBV) Up 9.7% Since Earnings Report: Can It Continue?

                              by Zacks Equity Research

                              AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Zacks Equity Research

                                Abbvie's Uterine Fibrosis Candidate Meets Goal in Study

                                by Zacks Equity Research

                                AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.

                                  Zacks Equity Research

                                  Novartis Psoriasis Drug Cosentyx Positive in SCALP Study

                                  by Zacks Equity Research

                                  Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.

                                    Zacks Equity Research

                                    AbbVie Presents New Data on Upadacitinib for Crohn's Disease

                                    by Zacks Equity Research

                                    AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

                                      Zacks Equity Research

                                      AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan

                                      by Zacks Equity Research

                                      AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.

                                        Zacks Equity Research

                                        Lilly's Taltz Positive in Phase III Label Expansion Study

                                        by Zacks Equity Research

                                        Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.

                                          Zacks Equity Research

                                          Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning

                                          by Zacks Equity Research

                                          Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning

                                            Sweta Killa headshot

                                            5 Solid Dividend Growth Stocks Amid Rising Rates

                                            by Sweta Killa

                                            Dividend growth stocks pose strong fundamentals and are lucrative, especially given the new tax legislation in the United States, rising yields and heightened volatility.

                                              Zacks Equity Research

                                              Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis

                                              by Zacks Equity Research

                                              Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

                                                Zacks Equity Research

                                                FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

                                                by Zacks Equity Research

                                                Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

                                                  Zacks Equity Research

                                                  Add These 7 GARP Stocks to Your Portfolio for Better Returns

                                                  by Zacks Equity Research

                                                  Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.